Potential of afatinib in the treatment of patients with HER2-positive breast cancer

tential of afatinib in the treatment of patients with HER2-positive breast cancer Review (1969) Total Article Views Authors: Geuna E, Montemurro F, Aglietta M, Valabrega G Published Date August 2012 Volume 2012:4 Pages 131 - 137 DOI: http://dx.doi.org/10.2147/BCTT.S25868 Received: 24 May 2012 Accepted: 04 July 2012 Published: 27 August 2012 Elena Geuna,1 Filippo Montemurro,2–4 Massimo Aglietta,1–3,5 Giorgio Valabrega1–3,5 1Division of Medical Oncology, Institute for Cancer Research and Treatment, Candiolo, Turin, 2Institute for Cancer Research, Candiolo, Turin, 3Foundation of Piedmont Oncology, Candiolo, Turin, 4Unit of Investigative Clinical Oncology, Candiolo, Turin, 5University Medical School of Turin, Turin, Italy Abstract: In the absence of treatment, overexpression of the human epidermal growth factor receptor 2 (HER2) predicts a poor prognosis in breast cancer. In the last decade, monoclonal antibodies and small molecule tyrosine kinase inhibitors have significantly improved the outcome of HER2-positive breast cancer patients. However, tumor resistance and toxicities often limit the use of these therapies. For this reason, there is a compelling need for further investigation of new targeted therapies, such as afatinib, an oral irreversible pan inhibitor of the epidermal growth factor receptor (EGFR) family. This compound covalently interacts with tyrosine kinase domains, which are deeply involved in signal transduction leading to cell proliferation and protection from apoptosis. Afatinib has been studied in several Phase I clinical trials in advanced solid tumors. These trials have shown encouraging clinical activity and manageable side effects when afatinib is used either as a single agent or in combination with chemotherapy, with cutaneous adverse events and diarrhea being the most frequently observed toxicities. This review will focus on afatinib’s clinical activity and will discuss ongoing clinical studies in HER2-positive breast cancer patients. In the scenario of the different HER2-targeted therapies, it will be important to define the best specific clinical and “molecular” setting for afatinib use, trying to identify predictors of resistance and response. Moreover, afatinib, which has the ability to cross the blood–brain barrier, could play a role in patients with brain metastases from breast cancer.